Pelthos Therapeutics (PTHS) has acquired Xeglyze from Hatchtech for $1.8M. Xeglyze is a pediculicide indicated for the topical treatment of head lice infestation in patients 6 months of age and older. The prescription medication was approved by the U.S. Food and Drug Administration in July 2020. The acquisition will provide Pelthos with the ability to commercialize Xeglyze worldwide, and there are no future milestone, royalty or other payments owed to Hatchtech. Pelthos plans to relaunch Xeglyze in the first half of 2027.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTHS:
- Pelthos Therapeutics Acquires Global Rights to Xeglyze
- Pelthos Therapeutics Adds Veteran Finance Executive to Board
- Pelthos Therapeutics Concludes 2025 Annual Stockholder Meeting
- Pelthos signs benefit manager agreement expanding patient access to ZELSUVMI
- Lake Street starts Pelthos with a Buy on ‘category-leader potential’